Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Digestive System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm

Cancer Family

Digestive System Neoplasm

CI-CAN-00000012Explore in graph →

Non-malignant4,733 active trials43 approved drugs557 evidence items

NCIt: C3052
MeSH: D004067
MeSH: D005770

Overview
Statistics
Survival
Genomics102
Variants & evidence557
Drugs121
Trials22059
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (1,073)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 901–925 of 1,073 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
· N Engl J Med · 2016 · PMID 27959684 · validated civic_curation pubmed
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
· Cancer Discov · 2013 · PMID 23729478 · validated civic_curation pubmed
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
· Br J Cancer · 2009 · PMID 19603018 · validated civic_curation pubmed
Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
· Cancer Discov · 2015 · PMID 25673644 · validated civic_curation pubmed
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
· Oncotarget · 2016 · PMID 26989027 · validated civic_curation pubmed
Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.
· Cold Spring Harb Mol Case Stud · 2016 · PMID 27626067 · validated civic_curation pubmed
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
· Ann Oncol · 2017 · PMID 28950338 · validated civic_curation pubmed

Showing 901–925 of 1,073 publications

← Previous
1
…
36
37
38
…
43
Next →

Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.

· J Gastrointest Oncol · 2017 · PMID 28480077 · validated civic_curation pubmed

Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.

· J Gastrointest Oncol · 2016 · PMID 28078132 · validated civic_curation pubmed

Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.

· Ecancermedicalscience · 2014 · PMID 25435907 · validated civic_curation pubmed

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.

· J Gastrointest Cancer · 2016 · PMID 26687137 · validated civic_curation pubmed

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

· Anticancer Res · 2011 · PMID 21508395 · validated civic_curation pubmed

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.

· Clin Cancer Res · 2016 · PMID 26933125 · validated civic_curation pubmed

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.

· J Natl Compr Canc Netw · 2017 · PMID 28874593 · validated civic_curation pubmed

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

· Ann Oncol · 2018 · PMID 29538669 · validated civic_curation pubmed

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

· Br J Cancer · 2015 · PMID 26633560 · validated civic_curation pubmed

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.

· Clin Cancer Res · 2019 · PMID 31068372 · validated civic_curation pubmed

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma.

· NPJ Precis Oncol · 2019 · PMID 31453370 · validated civic_curation pubmed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

· Cancer Discov · 2018 · PMID 29903880 · validated civic_curation pubmed

Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.

· JCO Precis Oncol · 2022 · PMID 35005993 · validated civic_curation pubmed

Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification.

· Oncologist · 2020 · PMID 32323889 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

· J Clin Oncol · 2011 · PMID 22025163 · validated civic_curation pubmed

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

· Clin Cancer Res · 2013 · PMID 23434733 · validated civic_curation pubmed

A novel K-ras mutation in colorectal cancer. A case report and literature review.

· Anticancer Res · 2009 · PMID 19661358 · validated civic_curation pubmed